Retrospective Study
Copyright ©The Author(s) 2024. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Gastrointest Oncol. May 15, 2024; 16(5): 1833-1848
Published online May 15, 2024. doi: 10.4251/wjgo.v16.i5.1833
Perioperative remedial antiviral therapy in hepatitis B virus-related hepatocellular carcinoma resection: How to achieve a better outcome
Fan Mu, Liang-Shuo Hu, Kun Xu, Zhen Zhao, Bai-Cai Yang, Yi-Meng Wang, Kun Guo, Jian-Hua Shi, Yi Lv, Bo Wang
Fan Mu, Liang-Shuo Hu, Zhen Zhao, Yi-Meng Wang, Kun Guo, Jian-Hua Shi, Yi Lv, Bo Wang, Department of Hepatobiliary Surgery, First Affiliated Hospital of Xi’an Jiaotong University, Xi’an 710061, Shaanxi Province, China
Kun Xu, Department of Anaesthesiology, First Affiliated Hospital of Xi’an Jiaotong University, Xi’an 710061, Shaanxi Province, China
Bai-Cai Yang, Department of Gynaecology, Wenzhou Medical University Affiliated Jiaxing Women and Children Hospital, Jiaxing 314000, Zhejiang Province, China
Author contributions: Mu F, Hu LS, and Wang B designed the research study; Mu F, Hu LS, Xu K and Zhao Z performed the research; Zhao Z, and Wang YM performed data analysis; Yang BC, Guo K, Shi JH, and Lv Y collected the data of patients; Mu F, Hu LS, Xu K, and Wang B contributed to writing the manuscript, drafting conception. All authors have read and approved the final the final manuscript.
Supported by National Natural Science Foundation of China, No. 82070649.
Institutional review board statement: The study was reviewed and approved by the Ethics Committee of the First Affiliated Hospital of Xi’an Jiao Tong University, No. XJTU1AF2021LSK-414.
Informed consent statement: Informed consent form exempted.
Conflict-of-interest statement: There is no conflict of interest.
Data sharing statement: All data and materials are available from the corresponding author.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Bo Wang, PhD, Chief Doctor, Department of Hepatobiliary Surgery, First Affiliated Hospital of Xi’an Jiaotong University, No. 277 Yanta Road, Xi’an 710061, Shaanxi Province, China. bobwang457@sina.com
Received: December 3, 2023
Peer-review started: December 3, 2023
First decision: January 15, 2024
Revised: January 25, 2024
Accepted: February 18, 2024
Article in press: February 18, 2024
Published online: May 15, 2024
Processing time: 158 Days and 5.7 Hours
Core Tip

Core Tip: Hepatocellular carcinoma (HCC) is the seventh most common cancer in the world and is usually associated with hepatitis B virus (HBV) infection. Radical resection and antiviral therapy are considered key clinical treatments for patients with HBV-related HCC. However, many patients have their HCC and HBV infection detected at the same time, so they receive remedial antiviral treatment beginning in the perioperative period, missing the opportunity for long-term preoperative antiviral therapy. Therefore, evaluating the clinical efficacy and relevant factors of perioperative remedial antiviral therapy will be valuable.